SEC Form 4 · accession 0001209191-15-053024
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jun 10, 2015
Accepted (ET)
Jun 12, 2015 · 8:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 10, 2015 | M | 1,300 | $17.16 | A | 346,584 | D | |
| Common Stock | Jun 10, 2015 | M | 10,400 | $35.64 | A | 356,984 | D | |
| Common StockF2,F3 | Jun 10, 2015 | S | 1,700 | $123.06 | D | 355,284 | D | |
| Common StockF3,F4 | Jun 10, 2015 | S | 1,400 | $124.29 | D | 353,884 | D | |
| Common StockF3,F5 | Jun 10, 2015 | S | 5,500 | $125.30 | D | 348,384 | D | |
| Common StockF3,F6 | Jun 10, 2015 | S | 3,100 | $125.91 | D | 345,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF7 | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $17.16 | Jun 10, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 7,000 | D |
| Stock Option (right to buy)F8 | $35.64 | Jun 10, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 344,000 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $123.06 (range $122.50 to $123.34).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $124.29 (range $123.72 to $124.67).
- F5Open market sales reported on this line occurred at a weighted average price of $125.30 (range $124.73 to $125.71).
- F6Open market sales reported on this line occurred at a weighted average price of $125.91 (range $125.75 to $126.14).
- F7Common stock held in grantor retained annuity trusts.
- F8Fully vested.